Meritage Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Meritage Group’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,180	Closed	-$322K	–	24
2024 Q2	$322K	Buy	1,180 +424	+56%	+$123K	0.01%	28
2024 Q1	$261K	Sell	756 -61	-7%	-$20.1K	0.01%	47
2023 Q4	$264K	Buy	+817	New	+$256K	0.01%	41
2023 Q3	–	Sell	-753	Closed	-$285K	–	54
2023 Q2	$285K	Buy	+753	New	+$306K	0.01%	27
2022 Q3	–	Sell	-469	Closed	-$232K	–	39
2022 Q2	$232K	Sell	469 -324	-41%	-$169K	0.01%	28
2022 Q1	$447K	Sell	793 -229	-22%	-$138K	0.01%	19
2021 Q4	$772K	Buy	1,022 +566	+124%	+$424K	0.01%	18
2021 Q3	$340K	Sell	456 -415	-48%	-$311K	0.01%	25
2021 Q2	$561K	Buy	871 +142	+19%	+$86.4K	0.01%	17
2021 Q1	$416K	Buy	729 +57	+8%	+$33.8K	0.01%	21
2020 Q4	$392K	Sell	672 -89	-12%	-$50.7K	0.01%	25
2020 Q3	$392K	Buy	+761	New	+$385K	0.01%	22

Other funds holding BIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Meritage Group's BIO Position: Q3 2024 in Review

Meritage Group sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2024, closing a stake of 1,180 shares — an estimated $322K sold.

Meritage Group first reported a position in BIO in Q3 2020 and held it in 12 quarters. The position peaked at $772K in Q4 2021. 438 funds tracked by Wall St. Rank hold BIO as of Q3 2024.

Meritage Group reported no remaining Bio-Rad Laboratories Class A position as of Q3 2024 after selling out during the quarter.
Meritage Group sold 1,180 Bio-Rad Laboratories Class A shares in Q3 2024, an estimated $322K.
Meritage Group first reported a position in Bio-Rad Laboratories Class A in Q3 2020 and held it in 12 quarters.
Meritage Group's Bio-Rad Laboratories Class A position peaked at $772K in Q4 2021.
438 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2024.

Based on Meritage Group's 13F filing for Q3 2024, filed 15 Nov 2024.